戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d anti-phosphatidyl-serine) and 1 in plasma (lupus anticoagulant).
2 reviously reported to be associated with the lupus anticoagulant.
3 n increased thrombotic risk in patients with lupus anticoagulant.
4 differed in sensitivity to the presence of a lupus anticoagulant.
5 he clotting test is used in the diagnosis of lupus anticoagulants.
6 mbin times is invalid for some patients with lupus anticoagulants.
7 monitored with a test that is insensitive to lupus anticoagulants.
8        Both monoclonal autoantibodies lacked lupus anticoagulant activity and did not inhibit prothro
9 hrombosis and women in the upper quartile of lupus anticoagulant activity had the highest risk.
10 ody was analyzed for its binding properties, lupus anticoagulant activity, and pathophysiologic activ
11 red endothelial cells in vitro, and some had lupus anticoagulant activity.
12 olamine, and phosphatidylserine), and showed lupus anticoagulant activity.
13 phospholipids/cofactors and vary in in vitro lupus anticoagulant activity.
14                                              Lupus anticoagulant and ACAs are made up of heterogeneou
15 present with thrombosis and are positive for lupus anticoagulant and ACAs have similar clinical prese
16                                     Isolated lupus anticoagulant and ACAs in children who are asympto
17 6.6%) were positive for aPL because they had lupus anticoagulant and/or high titer of anticardiolipin
18                                              Lupus anticoagulants and anticardiolipin antibodies have
19 n antigen specificities of autoantibodies in lupus anticoagulants and the mechanisms by which these a
20 bodies including anticardiolipin antibodies, lupus anticoagulants, and anti-beta(2) glycoprotein-1-sp
21            We report here experiments on how lupus anticoagulant antibodies (LA IgG) that react with
22 I, fibrinogen, lipoprotein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and geno
23 ecurrent fetal loss, and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti
24     All patients who had positive results of lupus anticoagulant, anticardiolipin, and anti-beta(2)-g
25                       Reactive antibodies to lupus anticoagulant, anticardiolipin, antithrombin III,
26 owever, establish that the autoantibodies in lupus anticoagulants are not directed against "native" a
27 n enzyme-linked immunosorbent assay (ELISA), lupus anticoagulant assays, and syphilis screening in ch
28                                              Lupus anticoagulants can influence prothrombin times and
29                                              Lupus anticoagulants comprise a heterogenous group of ci
30 ossibly the same epitope associated with the lupus anticoagulant, defined a small subset of children
31 annexin V, stands in marked contrast to the "lupus anticoagulant effect" previously described in thes
32                      All tested positive for lupus anticoagulant, had IgM antibodies to cardiolipin,
33                                            A lupus anticoagulant immunoglobulin was more inhibitory t
34 ardiolipin > or =40 IU/ml or the presence of lupus anticoagulant) in 42 patients (21%).
35 ting 151 patients with persistently positive lupus anticoagulant (LA) for a median period of 8.2 year
36         Nineteen of 28 patients with APS had lupus anticoagulant (LA) or high titers of anticardiolip
37               Data on the clinical course of lupus anticoagulant (LA)-positive individuals with or wi
38 line predictors of APOs included presence of lupus anticoagulant (LAC) (odds ratio [OR], 8.32 [CI, 3.
39 glycerides (all P < 0.0001), and presence of lupus anticoagulant (LAC) (P = 0.045) were associated wi
40 pid antibodies under the perception that the lupus anticoagulant (LAC) is prevalent in this populatio
41 e Caucasian ethnicity, smoking, alcohol use, lupus anticoagulant (LAC) positivity, and renal involvem
42 dsDNA], anti-Sm, anti-Ro, anti-La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody
43 esence of antiphospholipid antibodies (aPL), lupus anticoagulant (LAC), anti-beta2GPI antibody, and t
44 ence of anti-phospholipid (PL) Ab, including lupus anticoagulants (LAC) and/or anticardiolipin Ab (aC
45            Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodi
46                                Patients with lupus anticoagulants often have a prolonged prothrombin
47 well as elevated anticardiolipin antibodies, lupus anticoagulant, or a history compatible with antiph
48 r high levels of anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis.
49  level, were hypertensive, were positive for lupus anticoagulant, or had proteinuria.
50  with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis.
51 significantly associated with positivity for lupus anticoagulant (P < 0.0001) and anticardiolipin ant
52 trols, CVD patients were more likely to have lupus anticoagulant (P = 0.03), but less likely to be re
53  likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0.01).
54 and persistently positive anticardiolipin or lupus anticoagulant positive tests.
55 on laboratory and clinical manifestations of lupus anticoagulants, the pathogenetic mechanisms involv
56 id syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibod
57 ody was 1.53 (95% CI, 0.76-3.11), and with a lupus anticoagulant was 2.83 (95% CI, 0.83-9.64).
58                                              Lupus anticoagulant was a risk factor for unprovoked pro
59                                            A lupus anticoagulant was detected in four of five evaluat
60 s) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event
61                            For patients with lupus anticoagulants who were not receiving warfarin, pr

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。